https://www.selleckchem.com/pr....oducts/l-alpha-phosp
Background Previously proposed modifications to LI-RADS criteria for contrast-enhanced ultrasound (CEUS) performed using perfluorobutane contrast agent yielded increased sensitivity for hepatocellular carcinoma (HCC) without significant decrease in specificity. Objective To compare the diagnostic performance of CEUS with perfluorobutane using modified LI-RADS criteria versus contrast-enhanced CT or MRI using LI-RADS version 2018 (v2018) for characterizing lesions as HCC in high-risk patients. Methods This retrospecti
Curtir
Comentario
Compartilhar
